MAP1LC3A and Alzheimer disease: Next, we investigated whether the administration of PPP also affected Aβ degradation in astrocytes, and found that treatment with PPP also decreased LC3 immunostaining intensity in astrocytes around Aβ plaques in AD mice (Figure S10A,B, Supporting Information).